Long-term Results of Imatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia: A National Multicenter Prospective Study

Long-term Results of Imatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia: A National Multicenter Prospective Study

Objective: The discovery of imatinib was a milestone for chronic myeloid leukemia (CML). As the life expectancy of CML patients has approached that of the general population, research has shifted towards improving quality of life and economic considerations. After 2010, it was shown that some patien...

Full description

Bibliographic Details
Main Authors: Emine Merve Savaş, Seda Yılmaz, Ayşe Asena Başer Dikyar, Zübeyde Nur Özkurt, Ramazan Öcal, Ferda Can, Sezgin Pepeler, Lale Aydın Kaynar, Sanem Gökçen, Abdulkerim Yıldız, Murat Albayrak, Sema Karakuş, Özcan Çeneli, Münci Yağcı
Format: Article
Language:English
Published: Galenos Publishing House 2023-12-01
Series:Turkish Journal of Hematology
Subjects:
chronic myeloid leukemia
tyrosine kinase inhibitor
treatment-free survival
molecular relapse-free survival
Online Access:https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-49002

Internet

https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-49002

Similar Items